Entry Detail


General Information

Database ID: LDA0000951
Species: Homo sapiens
Confidence Score: 0.731059
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Yes
Clinical Significance: Unknown

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:HAS2-AS1
Full Name:HAS2 antisense RNA 1
Category:LncRNA
Species:Homo sapiens
Synonyms:HAS2-AS|HAS2AS|HASNT|NCRNA00077
Chromosome:8
Strand:+
Coordinate:
Start Site(bp):121639346End Site(bp):121645325
External Links:
Ensembl ID:ENSG00000248690
Ensembl Transcript ID:N/A
Entrez Gene:594842.0
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:10   
More Information
Causal Disease Number:8
Network:
Top Causal Diseases:
Glioma  (Score: 0.985791)
Glioma  (Score: 0.985791)
Breast Neoplasms  (Score: 0.731059)
Carcinoma, Ovarian Epithelial  (Score: 0.731059)
Glioblastoma  (Score: 0.731059)
Breast Neoplasms  (Score: 0.731059)
Carcinoma, Ovarian Epithelial  (Score: 0.731059)
Glioblastoma  (Score: 0.731059)
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:DOID:3068D005909
Disease Name:glioblastomaGlioblastoma
Category:Disease OntologyMeSH
Type:Neoplasms
Define:A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has_material_basis_in abnormally proliferating cells derives_from multiple cell types including astrocytes and oligondroctyes.A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Alias:GBM//adult glioblastoma multiforme//grade IV adult Astrocytic tumor//primary glioblastoma multiforme//spongioblastoma multiformeGlioblastoma//Glioblastomas//Astrocytoma, Grade IV//Astrocytomas, Grade IV//Grade IV Astrocytoma//Grade IV Astrocytomas//Glioblastoma Multiforme//Giant Cell Glioblastoma//Giant Cell Glioblastomas//Glioblastoma, Giant Cell//Glioblastomas, Giant Cell

 

Disease Association Statistics

Total Associated ncRNA Number:296   
More Information
Causal ncRNA Number:252
Network:
Top Causal ncRNAs:
DLEU1  (Score: 0.999893)
LINC-ROR  (Score: 0.999893)
MALAT1  (Score: 0.999893)
HOTAIRM1  (Score: 0.999893)
LINC-ROR  (Score: 0.999893)
MALAT1  (Score: 0.999893)
HOTAIRM1  (Score: 0.999893)
DLEU1  (Score: 0.999893)
hsa_circ_0029426  (Score: 0.985791)
DLGAP1-AS1  (Score: 0.985791)
More Information

 

Evidence Support

Strong Evidence:In Vivo Experiment//Western Blot//Transfection//Colony Formation Assay//CCK8//qRT-PCR//FISH//Luciferase Report Assay//IHC
Weak Evidence:

 

Reference

[1] PubMed ID:34094916
Disease Name:Glioblastoma
Sample:GBM cell lines
Dysfunction Pattern:Interaction(miR-137/LSD1)
Validated Method:In Vivo Experiment//IHC//Western Blot//Transfection//CCK8//qRT-PCR//FISH//Luciferase Report Assay//Colony Formation Assay
Description: HAS2-AS1 expression was upregulated in GBM cell lines, and HAS2-AS1 was localized mainly in the cytoplasm. Furthermore, HAS2-AS1 functioned as a ceRNA (competing endogenous RNA) of miR-137, leading to the disinhibition of its downstream target LSD1. The miR-137 level was downregulated by HAS2-AS1 overexpression and upregulated by HAS2-AS1 knockdown. In a subsequent study, LSD1 expression was negatively regulated by miR-137, while miR-137 reversed the LSD1 expression levels caused by HAS2-AS1.
Causality:Yes
Causal Description: In vitro, high HAS2-AS1 expression promoted proliferation, and knockdown of HAS2-AS1 significantly inhibited proliferation. Furthermore, HAS2-AS1 functioned as a ceRNA (competing endogenous RNA) of miR-137, leading to the disinhibition of its downstream target LSD1.
Clinical-realted Application: